AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study NCT04377139 — intervention group
Intervention type: PROCEDURE
Intervention: Prophylaxis
Description: The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
Study NCT04377139 — intervention group
Intervention type: PROCEDURE
Intervention: Preemptive
Description: The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
Study NCT01634204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KiloCoach
Description: Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted.
Study NCT01634204 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months.
Study NCT03152812 — intervention group
Intervention type: PROCEDURE
Intervention: plantar surface reconstruction by free flaps
Description: use of free skin or free muscle flaps for reconstruction of plantar surface
Study NCT02685774 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Description: Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
Study NCT01935557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous heparin infusion
Description: continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
Study NCT01935557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent heparin infusion
Description: Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
Study NCT03676816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal self sampling
Description: This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
Study NCT03676816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: provider-performed endocervical sampling
Description: provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
Study NCT03114527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
Study NCT03114527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTOR inhibitor
Study NCT02685774 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CKD-395 0.25/500mg
Description: CKD-395 0.25/500mg 2T oral administration
Study NCT01608048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation (TEAS);EA
Description: TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
Study NCT00949780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloral Hydrate
Study NCT01534468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Subvirion Vaccine, H7N7
Description: At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
Study NCT00298896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-595
Study NCT02880371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-382
Description: ARRAY-382 will be taken by mouth once daily at a fixed dose.
Study NCT03908229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trainee colonoscopy
Description: Colonoscopy performed by trainee
Study NCT02880371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
Study NCT02912481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior tibial artery
Study NCT02912481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery
Study NCT02912481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dorsalis pedis artery
Study NCT01086579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)
Description: Coronary Artery Bypass Graft (CABG)
Study NCT01086579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus (Paclitaxel eluting stent)
Description: Percutaneous transluminal coronary angioplasty (PTCA) with stent
Study NCT04693364 — intervention group
Intervention type: OTHER
Intervention: Decision Aid
Description: Use 3D printed breast model
Study NCT04693364 — intervention group
Intervention type: PROCEDURE
Intervention: Discussion
Description: Participate in consultation
Study NCT04693364 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03079258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
Study NCT01663272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABOZANTINIB
Description: Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
Study NCT01663272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
Study NCT01787513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBM
Description: CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
Study NCT01787513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CBM
Description: CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
Study NCT01787513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT
Description: iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
Study NCT01787513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iCBT
Description: iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
Study NCT03275727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iACT-BC
Description: A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
Study NCT03275727 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iACT-BC
Description: A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
Study NCT03908229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experienced physician colonoscopy
Description: Experienced physician colonoscopy
Study NCT01327989 — intervention group
Intervention type: DEVICE
Intervention: Solitaire™ FR device
Description: Mechanical Thrombectomy
Study NCT00310869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Developmental Care in the NICU
Description: Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
Study NCT01912391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
Study NCT01912391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Selegiline)
Description: Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
Study NCT02355366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Therapy
Description: Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
Study NCT02355366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Treatment
Description: Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
Study NCT01438346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Abuse Education
Description: 10 weeks of usual care for substance abuse.
Study NCT01438346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body Bridging
Description: Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
Study NCT02317302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET/MR
Study NCT02317302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Study NCT01922310 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours.
Study NCT02984176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Tab 40 mg
Description: 3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
Study NCT02984176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: 3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
Study NCT02845037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
Study NCT00699881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Study NCT04418206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patients COVID 19
Description: Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
Study NCT04375423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment and intervention: Behaviorally-dependent messaging
Description: In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
Study NCT04375423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological momentary assessment only
Description: Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
Study NCT04375423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment only
Description: Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
Study NCT03713489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet
Description: Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
Study NCT00127790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia (CBT-I)
Study NCT00127790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia (CBT-I)
Study NCT00127790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Pain (CBT-P)
Study NCT00127790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Pain (CBT-P)
Study NCT01340989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alteration of the insufflation gas
Description: addition of 4% oxygen
Study NCT01340989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C
Study NCT01340989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum
Description: no intervention besides the use of CO2
Study NCT04543422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Green tea extract capsules
Study NCT04543422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo containing inert material.
Study NCT00287911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
Study NCT00287911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
Study NCT00287911 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Some patients may also undergo brachytherapy
Study NCT00287911 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
Study NCT04101526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference
Description: Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
Study NCT02944578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.
Study NCT02944578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.
Study NCT03995238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-augmentation gait training
Description: Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
Study NCT03995238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-correction gait training
Description: Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
Study NCT03995238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised walking
Description: An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
Study NCT03660046 — intervention group
Intervention type: DRUG
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
Study NCT03660046 — intervention group
Intervention type: DRUG
Intervention: Etonogestrel implant (Eng-Implant)
Description: A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
Study NCT03660046 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUD (Lng-IUD)
Description: The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
Study NCT03393221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ER
Description: Emotion regulation content
Study NCT03393221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBWC
Study NCT03393221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBWC
Study NCT00614796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach, using a stepcounter with exercise counseling
Description: 5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
Study NCT00977067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0152
Description: Intravenous escalating dose
Study NCT00595569 — intervention group
Intervention type: BEHAVIORAL
Intervention: Flexible insulin therapy (FIT)
Description: Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each